OncLive TV

Peter Voorhees, MD, discusses CRS and infection data for etentamig from the phase 3 CERVINO trial in triple-class–exposed relapsed/refractory myeloma.

Peter Voorhees, MD, discusses phase 3 CERVINO data for etentamig vs standard therapies and next steps for the agent in relapsed/refractory myeloma.

Sagar Lonial, MD, FACP, FASCO, discusses MRD-negativity data with iberdomide plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, FASCO, discusses Project Optimus dose selection and MRD as an early end point in the phase 3 EXCALIBER-RRMM trial.

Brad S. Kahl, MD, discusses EA4181 findings, whether cytarabine is needed with BTK inhibition, and the future of chemotherapy-free care in mantle cell lymphoma

Dirk van Esser, MD, discusses safety with KRd in the EMN15/HOVON147 trial and how to select patients with high-risk smoldering myeloma for treatment.

Dirk van Esser, MD, discusses long-term EMN15/HOVON147 data for KRd vs Rd in high-risk smoldering multiple myeloma.

Jessica Encinas Mayoral, PhD, discusses preclinical data on an AI-designed BCMA/FcRL5 trispecific antibody in multiple myeloma.

Jessica Encinas Mayoral, PhD, discusses the design and antigen-independent activity of a BCMA/FcRL5 trispecific antibody in multiple myeloma.

Brad S. Kahl, MD, discusses how BTK inhibitors and MRD-guided treatment may help patients with frontline mantle cell lymphoma avoid transplantation.

Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how the treatment may reduce treatment burden for patients with polycythemia vera.

Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant and the clinical role of the ctDNA-guided switch paradigm introduced by SERENA-6.

Shimoli Barot, MD, considers how palbociclib maintenance could be sequenced with frontline T-DXd plus pertuzumab in HER2-positive metastatic breast cancer.

Ja Min Byun, MD, PhD, discusses response consistency and the future of mezigdomide plus elranatamab in multiple myeloma.

Ja Min Byun, MD, PhD, discusses updated phase 1 findings with mezigdomide plus elranatamab in relapsed/refractory multiple myeloma.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.

Shimoli Barot, MD, discusses PATINA data showing improved PFS with palbociclib-based maintenance in HR-positive, HER2-positive metastatic breast cancer.

Brad S. Kahl, MD, discusses how the TRIANGLE trial supports frontline therapy without autologous transplantation in mantle cell lymphoma.

Zev A. Wainberg, MD, discusses the phase 3 DAWN-303 trial of INCB161734 plus chemotherapy and the expanding role of KRAS inhibitors in pancreatic cancer.

Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Prithviraj Bose, MD, discusses spleen response and early survival data from the phase 3 SENTRY trial in JAK inhibitor-naive myelofibrosis.

William N. William Jr, MD, discusses the design, toxicity lessons, and TP53 co-mutant signal from the phase 2 AMIGO-1 trial of amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

Andrew Kuykendall, MD, discusses how hepcidin-upregulating agents could transform hematocrit control for patients with polycythemia vera.

Giada Bianchi, MD, discusses the design of the phase 3 CARES program evaluating anselamimab in AL amyloidosis.

Tapan M. Kadia, MD, details the dosing, tolerability, and response data with the use of dibotatug in patients with large granular lymphocytic leukemia.

Giada Bianchi, MD, discusses the mechanism of action for anselamimab in AL amyloidosis.

Gabriela S. Hobbs, MD, discusses how to distinguish proliferative from cytopenic myelofibrosis and the role of risk stratification.

Julia K. Rotow, MD, discusses why dual EGFR inhibition prevented acquired resistance mutations but did not extend PFS, and where the combination fits now.

Laura Alder, MD, discusses a retrospective analysis in which early-morning tarlatamab infusions during cycle 1 did not improve outcomes in small cell lung cancer, and what a prospective test would require.

Laura Alder, MD, discusses a multi-institutional real-world analysis of local consolidation and continued tarlatamab in patients with oligoprogressive small cell lung cancer.